



1614 *en*

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on August 31, 2005.

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT  
Examining Group 1614  
Patent Application  
Docket No. INN-112  
Serial No. 10/505,252

Frank C. Eisenschenk  
Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1614  
Applicants : Francois Romagne, Catherine Laplace  
Serial No. : 10/505,252  
Filed : August 19, 2004  
Conf. No. : 7415  
For : Methods for Producing Gamma Delta T Cells

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed below and on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited references are enclosed; however, Applicants have not submitted a copy of the U.S. patent cited on attached Form PTO/SB/08 pursuant to 37 CFR 1.98(a)(2)(ii).

Applicants have also provided an English language equivalent for international patent application WO 00/12516 (U.S. 6,660,723) and English language translation for international patent application WO 00/12519.

This information is being submitted prior to the mailing of a first office action on the merits.

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO/SB/08 with initials or other appropriate marks.

If any additional fee is required, or to credit any overpayment, please use Deposit Account No. 19-0065.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.56, 1.97, and 1.98 are met by the foregoing statements.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: Saliwanchik, Lloyd & Saliwanchik  
A Professional Association  
P.O. Box 142950  
Gainesville, FL 32614-2950

FCE/sssa

Attachments: Form PTO/SB/08  
Copies of references cited  
Copy of English language equivalent for international patent application  
WO 00/12516 (U.S. 6,660,723)  
Copy of English language translation for international patent application  
WO 00/12519



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/505,252
				Filing Date	August 19, 2004
				First Named Inventor	Francois Romagne
				Art Unit	1614
Examiner Name					
Sheet	1	of	3	Attorney Docket Number	INN-112

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US- 5,639,653	06-17-1997	Bloom B.R. <i>et al.</i>	ALL
	U2				
	U3				
	U4				
	U5				
	U6				
	U7				
	U8				
	U9				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup>	Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)			
	F1		WO 99/46365	09-16-1999	Emory University	ALL
	F2		WO 00/12516	03-09-2000	Institut National de la Sante et de la Recherche Medicale	ALL
	F3		WO 00/12519	03-09-2000	Institut National de la Sante et de la Recherche Medicale	ALL
	F4		WO 95/20673	08-03-1995	Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale	ALL

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/505,252
				Filing Date	August 19, 2004
				First Named Inventor	Francois Romagne
				Group Art Unit	1614
				Examiner Name	
Sheet	2	of	3	Attorney Docket Number	INN-112


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	BEHR, C. <i>et al.</i> "Plasmodium falciparum stimuli for human $\gamma\delta$ T cells are related to phosphorylated antigens of mycobacteria" <i>Infection and Immunity</i> , 1996, pp. 2892-2896, Vol. 64, No. 8.	
	R2	BORDIGNON, C. <i>et al.</i> "Cell therapy: achievements and perspectives" <i>Haematologica</i> , 1999, pp. 1110-1149, Vol. 84.	
	R3	CONSTANT, P. <i>et al.</i> "Stimulation of Human $\gamma\delta$ T Cells by Nonpeptidic Mycobacterial Ligands" <i>Science</i> , 1994, pp. 267-270, Vol. 264.	
	R4	CONSTANT, P. <i>et al.</i> "The Antituberculous <i>Mycobacterium bovis</i> BCG Vaccine Is an Attenuated Mycobacterial Producer of Phosphorylated Nonpeptidic Antigens for Human $\gamma\delta$ T Cells" <i>Infection and Immunity</i> , 1995, pp. 4628-4633, Vol. 63, No. 12.	
	R5	DAVISSON, V.J. <i>et al.</i> "Synthesis of Allylic and Homoallylic Isoprenoid Phyrophosphates" <i>Methods in Enzymology</i> , 1975, pp. 130-144, Vol. 110.	
	R6	DAVISSON, V.J. <i>et al.</i> "Phosphorylation of Isoprenoid Alcohols" <i>J. Org. Chem.</i> , 1986, pp. 4768-4779, Vol. 51.	
	R7	FOURNIE, J.J. <i>et al.</i> "Stimulation of $\gamma\delta$ T cells by phosphoantigens" <i>Res. Immunol. 66th Forum in Immunology</i> , 1996, pp. 338-347, Vol. 147.	
	R8	HINTZ, M. <i>et al.</i> "Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human $\gamma\delta$ T cells in <i>Echerichia coli</i> " <i>FEBS Lett.</i> , 2001, pp. 317-322, Vol. 509.	
	R9	KNORRE, D.G. <i>et al.</i> "General Method for the Synthesis of ATP Gamma-Derivatives" <i>FEBS Letters</i> , 1976, pp. 105-108, Vol. 70, No. 1.	
	R10	MUEHLBACHER, M. <i>et al.</i> "Isopentenyl-diphosphate isomerase: Inactivation of the Enzyme with Active-Site-Directed Irreversible Inhibitors and Transition-State Analogues" <i>Biochemistry</i> , 1988, pp. 7315-7328, Vol. 27.	
	R11	POCCIA, F. <i>et al.</i> "CD94/NKG2 Inhibitory Receptor Complex Modulates Both Anti-Viral and Anti-Tumoral Responses of Polyclonal Phosphoantigen-Reactive V $\gamma$ 9V $\delta$ 2 T Lymphocytes" <i>J. Immunol.</i> , 1997, pp. 6009-6017, Vol. 159.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/505,252
				Filing Date	August 19, 2004
				First Named Inventor	Francois Romagne
				Group Art Unit	1614
				Examiner Name	
Sheet	3	of	3	Attorney Docket Number	INN-112

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R12	POCCIA, F. <i>et al.</i> (1997) "γδ T cell activation or anergy during infections: The role of nonpeptidic TCR ligands and HLA class I molecules" <i>J. Leukocyte Biol.</i> , September 1997, pp. 287-291, Vol. 62.	
	R13	POQUET, Y. <i>et al.</i> "A novel nucleotide-containing antigen for human blood γδ T lymphocytes" <i>Eur. J. Immunol.</i> , 1996, pp. 2344-2349, Vol. 26.	
	R14	POQUET, Y. <i>et al.</i> "High-pH Anion-Exchange Chromatographic Analysis of Phosphorylated Compounds: Application to Isolation and Characterization of Nonpeptide Mycobacterial Antigens" <i>Anal. Biochem.</i> , 1996, pp. 119-126, Vol. 243.	
	R15	SCIAMMAS, R. <i>et al.</i> "TCR γδ cells and viruses" <i>Microbes and Infection</i> , 1999, pp. 203-212, Vol. 1.	
	R16		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.